Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma
NCT ID: NCT03159819
Last Updated: 2018-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
24 participants
INTERVENTIONAL
2017-04-01
2021-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
NCT05472857
Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors
NCT05393986
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
NCT03874897
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
NCT03302403
CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor
NCT03182816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objectives:
Determine the safety, tolerability and cytokinetics of the autologous T cells transduced with anti-Claudin18.2 lentiviral vector in patients with gastric adenocarcinoma and pancreatic adenocarcinoma.
Secondary objectives:
Make a preliminary evaluation on the efficacy of CAR-CLD18 T cells in patients with gastric adenocarcinoma and pancreatic adenocarcinoma with the following parameters:
Time of tumor progression (TTP);
Disease Control Rate (DCR);
Objective Remission Rate (ORR);
Overall Survival (OS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CAR-CLD18 T cells
Autologous T Cells with a Claudin18.2-redirected Chimeric Antigen Receptor. Route of administration: Intravenous injection.
Lymphodepletion conditioning regimen will be applied prior to CAR-CLD18 T cell infusion.
CAR-CLD18 T Cells
Dose escalation will be applied in this study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CAR-CLD18 T Cells
Dose escalation will be applied in this study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Biopsy confirmation of Claudin18.2 positive.
3. Patients with advanced gastric adenocarcinoma who have not been cured with second line chemotherapy, and who are not willing to undergo second line chemotherapy after the failure of first line chemotherapy. (1) Failure of treatment is defined as disease progression, recurrence or metastatic disease, or intolerable toxicities occurred after treatment. (2) Each line of treatment during the period of disease progression includes one or more chemotherapy drugs which are administered for not less than one cycle or even longer. Neoadjuvant/adjuvant therapy can be applied at an earlier stage of treatment. If patient has developed recurrence or metastatic disease within 24 weeks of neoadjuvant/adjuvant therapy, it is considered as one line of systemic chemotherapy. (3) Therapies that can be performed at an earlier stage are chemotherapy in conjunction with molecular targeted drugs.
4. Patients with advanced/metastatic pancreatic adenocarcinoma which has relapsed after surgery or for which there is no surgical indication, who have not been cured with or refused to receive other standard regimens.
5. Expected survival after first dose of study drug \> 12 weeks.
6. At least one measurable lesion (≥ 10 mm) for imaging assessment.
7. ECOG scores 0 - 1.
8. Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.
9. White blood cells (WBCs) ≥ 2.5×10\^9/L Platelets (PLT) ≥ 100×10\^9/L Hemoglobin, Blood (Hb) ≥ 9.0 g/dL MID ≥ 1.5×10\^9/L Lymphocyte (LY) ≥ 0.47×10\^9/L LY% ≥ 15%
10. Serum albumin (Alb) ≥ 30 g/L
11. Serum lipase (LPS) and serum amylase \< 1.5 ULN
12. Serum creatinine ≤ 1.5 ULN
13. Alanine aminotransferase (ALT) ≤ 2.5 ULN Aspartate aminotransferase (AST) ≤ 2.5 ULN If osseous metastasis or liver metastasis is developed and alkaline phosphatase (ALP) \> 2.5 ULN, ALT and AST \< 1.5 ULN.
14. Serum total bilirubin (TBIL) ≤ 1.5 ULN
15. Prothrombin Time (PT): International Normalized Ratio (INR) \< 1.7. PT \< (ULN + 4) s
All test results should be within their normal ranges, and the patient is not receiving continuous supportive care.
Exclusion Criteria
1. Pregnant or lactating women.
2. HIV positive, HCV positive, HBV DNA copies ≥ 10\^3.
3. Uncontrolled active infection.
4. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
5. Allergic to immunotherapies and related drugs.
6. Untreated brain metastases or having symptoms of brain metastases.
7. Metastases to the lung: central tumor or multiple metastases.
8. Patients with heart disease for which treatment is needed or with poorly controlled hypertension.
9. Patients with unstable or active peptic ulcer or with alimentary tract hemorrhage.
10. Patients with previous organ transplantation or in preparation for organ transplantation.
11. Patients in need of anticoagulant treatment (e.g. warfarin or heparin).
12. Patients in need of long-term antiplatelet treatment (aspirin, dosage \> 300 mg/d; clopidogrel, dosage \> 75 mg/d).
13. Previous treatment with chemoradiotherapy and tumor-targeting drug which were conducted 4 weeks prior to the study (blood collection).
14. Patients have undertaken major surgeries or have been badly injured 4 weeks before the study (blood collection), or will undertake major surgeries during the study.
15. The judgment of investigators that the patient is not able to or not willing to follow the instructions of the protocol.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CARsgen Therapeutics Co., Ltd.
INDUSTRY
Changhai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bin Wang
Attending physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xianbao Zhan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Changhai Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Changhai Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CG4003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.